3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
2
Obesity
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Overweight
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Lung Neoplasms
1
Localized Prostate Cancer
1
Leukemia
1
Leiomyosarcoma
1
Interventions
palbociclib
1
microcrystalline cellulose
1
epigallocatechin gallate
1
dapagliflozin
1
Vitamin D
1
Tablets
1
Specimen Handling
1
Selenium
1
Saline Solution
1
Pregabalin
1
Platelet Count
1
Plastic Surgery Procedures
1
Omeprazole
1
Losartan
1
Ketorolac
1
Infliximab
1
Immunotherapy, Adoptive
1
Dexmedetomidine
1
Cognitive Behavioral Therapy
1
Calcium
1
Bevacizumab
1
Ascorbic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Inflammation
×
Tablets
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled